Unknown

Dataset Information

0

Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.


ABSTRACT: Defining mucosal immune responses and inflammation to candidate human immunodeficiency virus type 1 (HIV-1) vaccines represents a current research priority for the HIV-1 vaccine field. In particular, it is unclear whether intramuscular immunization can elicit immune responses at mucosal surfaces in humans.In this double-blind, randomized, placebo-controlled clinical trial, we evaluated systemic and mucosal immune responses to a candidate adenovirus serotype 26 (Ad26) vectored HIV-1 envelop (Env) vaccine in baseline Ad26-seronegative and Ad26-seropositive healthy volunteers. Systematic mucosal sampling with rectal Weck-Cel sponges and rectal biopsies were performed.Intramuscular immunization elicited both systemic and mucosal Env-specific humoral and cellular immune responses in the majority of subjects. Individuals with preexisting Ad26-specific neutralizing antibodies had vaccine-elicited immune responses comparable to those of subjects who were Ad26 seronegative. We also observed no increase in activated total or vector-specific mucosal CD4+ T lymphocytes following vaccination by either histopathology or flow cytometry.These data demonstrate that a single intramuscular administration of this Ad26-vectored HIV-1 Env vaccine elicited both systemic and mucosal immune responses in humans. Induction of antigen-specific humoral and cellular mucosal immunity was not accompanied by a detectable increase in mucosal inflammation.NCT01103687.

SUBMITTER: Baden LR 

PROVIDER: S-EPMC4318919 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Defining mucosal immune responses and inflammation to candidate human immunodeficiency virus type 1 (HIV-1) vaccines represents a current research priority for the HIV-1 vaccine field. In particular, it is unclear whether intramuscular immunization can elicit immune responses at mucosal surfaces in humans.<h4>Methods</h4>In this double-blind, randomized, placebo-controlled clinical trial, we evaluated systemic and mucosal immune responses to a candidate adenovirus serotype 26  ...[more]

Similar Datasets

| S-EPMC3532831 | biostudies-literature
| S-EPMC3532832 | biostudies-literature
| S-EPMC8855837 | biostudies-literature
| S-EPMC4648371 | biostudies-literature
2022-02-23 | GSE190850 | GEO
| S-EPMC5681732 | biostudies-literature
| S-EPMC10715068 | biostudies-literature
| S-EPMC6450945 | biostudies-literature
| S-EPMC5309930 | biostudies-other
| S-EPMC4086631 | biostudies-literature